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Abstract
Background: The EWS-FLI-1 fusion protein is associated with 85–90% of Ewing’s sarcoma family tumors (ESFT), the
remaining 10–15% of cases expressing chimeric genes encoding EWS or FUS fused to one of several ets transcription factor
family members, including ERG-1, FEV, ETV1 and ETV6. ESFT are dependent on insulin-like growth factor-1 (IGF-1) for growth
and survival and recent evidence suggests that mesenchymal progenitor/stem cells constitute a candidate ESFT origin.
Methodology/Principal Findings: To address the functional relatedness between ESFT-associated fusion proteins, we
compared mouse progenitor cell (MPC) permissiveness for EWS-FLI-1, EWS-ERG and FUS-ERG expression and assessed the
corresponding expression profile changes. Whereas all MPC isolates tested could stably express EWS-FLI-1, only some
sustained stable EWS-ERG expression and none could express FUS-ERG for more than 3–5 days. Only 14% and 4% of the
total number of genes that were respectively induced and repressed in MPCs by the three fusion proteins were shared.
However, all three fusion proteins, but neither FLI-1 nor ERG-1 alone, activated the IGF1 promoter and induced IGF1
expression.
Conclusion/Significance: Whereas expression of different ESFT-associated fusion proteins may require distinct cellular
microenvironments and induce transcriptome changes of limited similarity, IGF1 induction may provide one common
mechanism for their implication in ESFT pathogenesis.
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Introduction
Ewing’s sarcoma family tumors are associated with non-random
chromosomal translocations that generate fusion genes which
encode aberrant transcription factors [1,2]. The most common
chromosomal translocation, associated with 85% of ESFTs is
t(22;11)(q24;q12 ), which generates the EWS-FLI-1 fusion [3]. The
t(21;22)(q22;q12) translocation is associated with about 10% of
tumors and leads to EWS-ERG formation, whereas the remaining
1–5% of ESFT bear translocations that generate FUS-ERG,
EWS-FEV, EWS-ETV1 and EWS-ETV4 fusions [1,4]. In all
cases, the transactivation domain of one of the TET (TLS/FUS,
EWS, TAFII68) family of proteins is fused to the DNA binding
domain-containing region of an ets transcription factor family
member [1,4].
The fusion proteins associated with ESFT are believed to
provide the oncogenic stimulus that transforms primary cells, at
least in part by altering their transcriptome. In NIH 3T3 cells,
different ESFT-associated fusion genes have been observed to
induce a similar tumor phenotype [5]. However, EWS-FLI-1
induces an oncogenic stress-type response in primary human and
mouse fibroblasts [6,7], suggesting that a distinctly permissive
cellular environment may be required for EWS-FLI-1-mediated
oncogenesis. Recent evidence indicates that primary bone
marrow-derived MPCs are permissive for EWS-FLI-1 expression
as well as its transforming effects and that EWS-FLI-1 expression
may constitute the initiating event in ESFT pathogenesis [8]. In
contrast to other primary or transformed heterologous cells
transduced with EWS-FLI-1, MPCs expressing EWS-FLI-1
(MPCEWS-FLI-1) displayed a transcriptome consistent with survival,
proliferation and invasion [8]. Among potentially relevant genes
found to be induced in MPCs but not in other primary cells
infected with EWS-FLI-1-containing vectors was IGF-1, which
constitutes a key growth factor for ESFT survival [8]. These
observations suggest that IGF-1 may be an EWS-FLI-1 target in a
permissive cellular context that may constitute an origin of ESFT.
Most studies on ESFT fusion proteins have been conducted on
EWS-FLI-1, given that the frequency of its association with ESFT
is by far the highest. Several of these studies have shown that the
target gene repertoire of EWS-FLI-1 varies according to the host
cell type [9,10]. To determine whether EWS-FLI-1 and other
ESFT-associated fusion proteins trigger similar responses in cells
from which ESFT are believed to originate, we stably introduced
EWS-FLI1, EWS-ERG and FUS-ERG into MPC and addressed the
corresponding transcription profile changes. We compared these
changes to those induced by FLI1 and ERG1 alone as well as to
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those induced by an isoform of FUS-ERG associated with acute
myeloid leukemia (AML) but not ESFT [11]. Our results show
that MPCs display differential permissiveness for EWS-FLI-1,
EWS-ERG and FUS-ERG and that among the gene expression
changes induced by the three fusion proteins only a limited
fraction are shared. One of the genes observed to be induced by all
three fusion proteins was IGF1. In the present work we provide
evidence that IGF1 is a direct target gene of ESFT fusion proteins.
Results
Expression of ESFT fusion proteins in mesenchymal
progenitor cells
The Ewing’s sarcoma EWS-FLI1, EWS-ERG and FUS-ERG
fusion genes, the AML FUS-ERG fusion and the human FLI1 and
ERG1 genes were RT-PCR amplified as described in materials
and methods. A schematic representation of all the constructs is
shown in Figure 1. An EWS-FLI1 mutant encoding the R340N
mutation in the DNA binding domain of FLI-1 was generated to
serve as a control for DNA binding-dependent versus DNA
binding-independent effects. The R340N mutant (DNA-binding
mutant, DBDM) has been shown to conserve some degree of
transforming capacity in NIH3T3 fibroblasts despite lacking DNA
binding activity [12].
Three independently isolated C57Bl6 mouse MPC populations
were derived from the bone marrow, and three to four replicate
infections were performed for each construct. Thus, the same
MPC populations were used to test the expression and effect of
each fusion and wt protein, eliminating the possibility that any
difference in the effects of the proteins might reflect differences
among the primary MPC batches. Expression of all three fusion
proteins induced mild but readily detectable morphological
changes of the MPCs, characterized by loss of the elongated
spindle shape and rounding. By contrast, cells expressing the DNA
binding mutant of EWS-FLI-1 maintained the characteristic MPC
spindle shape as did cells expressing FLI-1 and ERG-1 alone
(Figure 2). No change in the expression of mesenchymal stem cell
markers, as assessed by FACS analysis, was observed in any of
these populations (data not shown).
Expression of the fusion and wild type proteins was tested by
Western blot analysis. All of the fusion proteins as well as FLI-1
and ERG-1 were readily detected 36 hours following infection
(Figure 3A). Densitometric analysis revealed that EWS-FLI-1,
EWS-ERG and the ESFT-associated FUS-ERG isoform were
expressed at comparable levels, whereas the DBDM, FLI-1, ERG-
1 and the AML-associated FUS-ERG isoform displayed a 1.5 to
2.5 fold higher expression level (Figure S1). Expression of wild type
FLI-1 and ERG-1, as well as that of the DBDM was stably
maintained by MPCs infected with the corresponding viruses
(Figure 3 B); EWS-FLI-1 protein expression was also stably
maintained by MPCs, but at a 4-, 2- and 7 fold lower level than
the DBDM and the FLI-1 and ERG-1 proteins, respectively, as
assessed by densitometric analysis (Figure 3 B and Figure S1).
Comparable expression levels of each of these proteins were
observed in independently infected cells derived from the same
primary population and in different MPC populations (data not
Figure 1. Schematic representation of EWS-FLI-1, EWS-ERG, FUS-ERG (AML) and FUS-ERG (ESFT) fusion proteins and human ERG-1
and FLI-1 proteins. Amino acid sequences at the breackpoints of each chimera are annotated and breakpoints on ERG-1 and FLI-1 are indicated by
arrows.
doi:10.1371/journal.pone.0002634.g001
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shown). However, the same MPC populations displayed variable
ability to maintain EWS-ERG expression and were unable to
stably express either of the two FUS-ERG fusion proteins (Figure 4
and data not shown). The EWS-ERG fusion protein was
maintained beyond 14 days of culture and selection in only one
out of three MPC populations tested (figure 4A, lanes 3, 6, 9). Both
genomic DNA and total RNA from cells that had lost EWS-ERG
protein expression tested positive for the presence of EWS-ERG
by PCR or RT-PCR using EWS-ERG specific primers. In some
samples, RT-PCR analysis showed that loss of protein expression
was accompanied by non-random EWS-ERG RNA processing
(figure 4B, lane 4), reflected by the presence of two distinct
transcripts of about 250 and 500 bp. PCR-amplification using
primers complementary to the 59end of EWS and the 39end of
ERG and subsequent sequence analysis of the amplicons revealed
that the lower band was composed of the initial 59 175 bases of
Figure 3. Expression in mouse MPCs of human FLI-1 and ERG-1 , ESFT-associated fusion proteins EWS-FLI-1 (EF), EWS-ERG (EE) and
FUS-ERG (FE), the AML-associated FUS-ERG fusion protein variant and the EWS-FLI-1 R340N DBD mutant. Mouse MPCs were infected
with human ERG-1 (A and B lane 4), human FLI-1 (A and B, lane 2), EWS-FLI-1 (A and B, lanes 7), EWS-FLI-1 R340N DBD mutant (A and B, lanes 8), EWS-
ERG (A and B, lanes 6), FUS-ERG ESFT (lane 10), FUS-ERG AML (lane 11), or an empty pMSCV puro vector (A, lanes 1,3,5,9; B lanes 1, 3, 5). Cells were
harvested 36 hours after the infection (A) or selected in 1.5 mg/ml puromycin for a period of 14 days (B). Protein expression was assessed by western
blot analysis using a mouse anti v5 epitope (A, lanes 3–11; B, lanes 3–8) or a mouse anti human FLI-1 monoclonal antibody (A and B lanes 1–2). The
secondary antibody was an HRP-conjugated goat anti mouse IgG. Monoclonal mouse anti-actin antibody was used as a loading control. With the
exception of EWS-ERG in selected cells (B, lane 6), bands are representative of expression levels obtained in 3 independent MPC populations.
doi:10.1371/journal.pone.0002634.g003
Figure 2. Phenotype of mouse MPCs infected with EWS-FLI-1, EWS-FLI-1 R340N mutant, EWS-ERG, FUS-ERG ESFT, FUS-ERG AML,
ERG-1, FLI-1 or an empty pMSCV puro vector. Images were taken 3 days after infection (200X magnification).
doi:10.1371/journal.pone.0002634.g002
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EWS fused to the 39 57 bases of ERG and the V5 tag. The higher
band consisted of the 59 333 coding bases of EWS fused to the 39
139 coding bases of ERG and the V5 tag. In both cases the Ewing’s
sarcoma breakpoint was lost and translation showed no open
reading frame (data not shown). No deamination was observed
within the sequence suggesting the absence of RNA editing, and
no point mutations were found in the EWS/ERG sequence.
Expression of both FUS-ERG fusion proteins was limited to no
more than 3–5 days. Cells surviving puromycin selection tested
positive for FUS-ERG DNA integration into the host genome
(figure 4D) but were negative for FUS-ERG RNA expression.
Cell cycle analysis (Figure S2) showed that 36 hours following
infection, prior to puromycin selection, only a small fraction of
cells underwent apoptosis, with no significant difference among the
different fusion gene-containining vector-infected cells (data not
shown). At later time points, under puromycin selection, all of the
populations displayed higher fractions of apoptotic cells. However,
there was little difference in the apoptotic cell fractions among
Figure 4. Variability of EWS-ERG expression in mouse MPCs. A) Western blot analysis: three independent MPCs populations were infected
with human ERG-1 (lanes 2, 5 and 8), EWS-ERG (lanes 3, 6 and 9) or an empty pMSCV puro vector (lanes 1,4 and 7). After confirming ERG-1 and EWS-
ERG expression at the protein level 36 hours following infection (data not shown), cells were selected with 1.5 mg/ml puromycin for 14 days, and
protein expression was re-assessed using a mouse anti v5 epitope mAb and a goat anti mouse-HRP conjugated antibody. Monoclonal mouse anti-
actin was used as a loading control. (B) RT-PCR analysis of EWS-ERG infected MPC populations. RNA was extracted from puromycin-selected MPCs
populations expressing (lanes 1 and 6) or not (lanes 2 and 4) EWS-ERG protein and from puromycin-selected MPC populations infected with an empty
pMSCV puro vector (lanes 3 and 7). RT-PCR was performed using primers complementary to the 59end of EWS and at the 39end of ERG. A control
lacking RT was included (lane 5) as well as a mouse b-actin amplification RNA control. (C) Genomic DNA analysis of EWS-ERG infected MPC
populations. Lanes1 and 3: puromycin-selected MPC populations lacking EWS/ ERG protein (A lane 3) and showing degraded EWS-ERG RNA (B lane 4).
Lanes 2 and 4: puromycin-selected MPC populations infected with an empty pMSCV puro vector. PCR was performed using primers either at the
59end of EWS and at the 39end of ERG-1 (lanes 3 and 4) or primers located on the pMSCV vector (lanes 1 and 2). D) Genomic DNA analysis of FUS-ERG
infected MPCs populations. Genomic DNA was extracted from puromycin-selected MPCs populations infected with ESFT-associated FUS-ERG (lane 3),
AML-associated FUS-ERG (lane 2) or an empty pMSCV puro vector (lane 1). PCR was performed using primers complementary to the 59end of EWS
and to the 39end of FUS.
doi:10.1371/journal.pone.0002634.g004
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populations expressing the different fusion genes. In fact, the
highest fraction of apoptotic cells seemed to be found in the EWS-
FLI-1 expressing cell population, suggesting that apoptosis was not
the main cause of the loss of EWS-ERG and FUS-ERG protein
expression.
Gene expression profiles of MPCs containing ESFT fusion
proteins, FLI-1 and ERG-1 display limited similarity
Transcriptional changes were analysed 36 hours and 4 days
following infection, when expression of all of the fusion proteins
and that of the corresponding wild type ets family proteins was
comparable. No significant difference in the gene expression
profile induced by the various fusion genes at 36 hours and 4 days
was observed (data not shown). The number of genes observed to
be induced and repressed differed among cells expressing the three
fusion proteins, with a higher number of genes being affected by
EWS-FLI-1 and FUS-ERG than by EWS-ERG. Using a 5% false
discovery rate, cells expressing EWS-ERG displayed 67 repressed
and 144 induced genes, whereas EWS-FLI-1 and FUS-ERG
expressing cells had 199 and 172 repressed and 250 and 208
induced transcripts, respectively (Table S1, Figure 5).
Consistent with the notion that a predominantly gene
expression inducing transcriptional activity is associated with
ESFT fusions [13,14], pairwise comparison revealed greater
similarity among the induced than among the repressed transcript
repertoires (Figure 5). Thus, of all of the genes induced in cells
infected with EWS-FLI-1 and EWS-ERG retroviruses, ,40%
were shared whereas only,13% of those that were repressed were
common. EWS-ERG and FUS-ERG expressing cells shared about
21% of the induced but less than 12% of repressed transcript
repertoire, similar to EWS-FLI-1 and FUS-ERG expressing cells
that shared 22% of their induced and 10% of their repressed genes
(Table S1 and Figure 5). Fifty-seven induced (14% of the total) and
13 repressed (4% of the total) transcripts were common to all three
fusion proteins (Figure 5 and Table S1). The same comparison
revealed somewhat greater similarity between EWS-FLI-1 and
EWS-ERG induced genes than between genes induced by either
fusion and those induced by FUS-ERG, suggesting a potentially
important role of the N-terminal portion of the fusions in target
gene selection. In contrast to the limited but nevertheless
significant overlap of induced and repressed transcripts in response
to the three fusion proteins, ERG-1 and FLI-1 shared very few
common targets in MPCs. Whereas ERG-1 induced 122 and
repressed 329 transcripts, and FLI-1 induced 290 and repressed
169 transcripts, only 14 of the induced (3.5%) and 8 of the
repressed transcripts (1.6%) were common to the two transcription
factors (Figure 5).
Similarity between the effects of FLI-1 and ERG-1 and those of
their corresponding fusion proteins was also limited to a restricted
number of genes (Figure 5). Thus, about 20% of all of the genes
induced and repressed by EWS-ERG were also induced and
repressed by ERG-1 alone and less than 8% of genes induced and
repressed by EWS-FLI-1 were induced and repressed by FLI-1 alone.
The role of the DNA binding domain in the transcriptional
activity of EWS-FLI-1 fusion protein was addressed by comparing
the transcriptional activity of wt EWS-FLI-1 with that of the
DBDM. The EWS-FLI-1 DBDM induced 98 and repressed 167
transcripts in MPCs compared to, respectively, 250 induced and
199 repressed transcripts by wt EWS-FLI-1, suggesting that
impairment of EWS-FLI-1 DNA binding affects the transcrip-
tional activation capacity of the fusion more strongly than its
transcriptional repression capacity. Pairwise comparison revealed
that only 65 out of a total of 649 (,10%) genes that were induced
and repressed were shared (Figure 5).
Finally, comparison between the effects on MPCs of FUS-ERG
fusions found in ESFT and AML revealed a similar number of
induced and repressed transcripts. Of the total induced transcripts
by the two fusion proteins, about 34% were common whereas
about 22% of all of the repressed transcripts were shared between
cells expressing the two fusions (Figure 5, Table S1).
Distinct and common candidate target genes of ESFT
fusion proteins and their component ets family members
Expression of fifteen of the genes that were found to be
significantly up- or down-regulated in MPC expressing EWS-
FLI1, EWS-ERG and FUS-ERG was validated by quantitative
real-time PCR in the corresponding cells as well as in FLI-1 and
ERG-1 expressing counterparts (a complete list of up- and
downregulated genes is provided in Table S2, whereas shared
genes are listed in Table S3). DHH, PODXL, KRT119 and CDH5
were up-regulated in FLI-1 and ERG-1-expressing cells as well as in
all three fusion protein expressing MPCs (Table 1). By contrast,
CITED1, SFRP4, IGF1, IGFBP5, IGFBP3 and ENO3 were among
genes that were upregulated in all three fusion protein containing
cells but not in cells expressing FLI-1 and ERG-1 alone (Table 1).
Several other genes, including DCN, MT2, DKK3, DKK2 andMMP3
displayed movement in one or two fusion protein containing cells
but not in FLI-1 and ERG-1 retrovirus-infected cells.
Comparison of the expression of these same genes in cells
expressing EWS-FLI-1 and the EWS-FLI-1 DBDM revealed that
IGFBP3, PODXL, KRT119 and CDH5 were induced in both cell
types, albeit substantially more strongly in wt EWS-FLI-1
expressors for all except IGFBP3 (Table 2). By contrast, DHH,
IGF1, IGFBP5 and ENO3 were upregulated in wt EWS-FLI-1
expressing cells only. CITED1 was upregulated in both but more
than 150 times more strongly in EWS-FLI-1 expressing cells
(Table 2).
When the effects of the two FUS-ERG fusions in MPCs were
compared, all of the genes tested displayed movement in the same
direction. The only difference was that the degree of induction of
each gene was 1.25 (DHH) to more than 10 (IGFBP3) times greater in
cells expressing the AML-associated fusion (Table 3). It is conceivable
that the stronger induction associated with the AML than with the
ESFT fusion is a reflection of the higher expression level of the AML
fusion protein that appears to be tolerated in MPCs.
Among the other putative gene targets, CITED1, which is a
major discriminator of human ESFT with respect to other
sarcomas [15] was strongly induced by the fusion proteins but
only weakly by the DBDM. DHH and SFRP4 were both induced
by wt fusion proteins but not by the DBDM, whereas PODXL,
KRT119 and CDH5 were induced both by FLI-1 and ERG-1 alone
and by the EWS-FLI-1 DBDM. These observations suggest that
the DBDM conserves some transcriptional or transcription co-
factor activity, consistent with the report that it maintains a degree
of transforming ability in NIH3T3 cells [12].
EWS-FLI-1 recognizes the IGF1 promoter
To address the interaction between EWS-FLI-1 and the IGF1
promoter in vivo, chromatin immunoprecipitates (ChIP) from
lysates of mouse MPCs expressing EWS-FLI-1, the DBDM and
the empty vector were subjected to quantitative RT-PCR using
primers specific for the region stretching from –2754 nucleotides
to –2683 nucleotides upstream of the exon 1 start codon
(ENSMUSE00000369489) of the murine IGF1 promoter
(Figure 6A). This 70 bp stretch corresponds to the sequence
annotated as –408 to –338 of the murine IGF1 promoter in a
recent report by Alfieri et al. [16] and is included in the putative
murine IGF1 promoter region GXP_41004 defined by the
Ewing’s Sarcoma Fusion Targets
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Figure 5. Venn diagrams indicating the extent of overlap of the transcription profiles of MPCs expressing the three ESFT-
associated fusion proteins, ERG-1, FLI-1, the EWS-FLI-1 R340N mutant and the AML-associated FUS-ERG fusion protein. A white
asterisk marks the areas where Igf1 is commonly present.
doi:10.1371/journal.pone.0002634.g005
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Genomatix (http://www.genomatix.de) genome annotation tool
‘‘Eldorado’’. This region shows the highest similarity (96%) to the
human IGF1 promoter region GXP_79580 and, by Genomatix
analysis, is suggested to contain several potential trancription
factor binding sites including ets binding sites. Relative to empty
vector-expressing cells, a 5 fold increase in IGF1 promoter
occupancy by the fusion protein was observed in ChIP assays
directed against the anti-V5 epitope on the EWS/FLI-1 fusion
protein.
EWS-FLI-1 expressing cells displayed a 9 fold increase in IGF1
message as measured by quantitative real time PCR (Figure 6B).
No IGF1 promoter occupancy was observed in chromatin
immunoprecipitates from the DBDM expressing cells, which also
displayed no induction of IGF1 transcripts (Figure 6). Similarly, no
enrichment was observed using a second set of primers amplifying
a region located about 14000 bp upstream of the IGF1 exon 1 start
codon containing no putative ets binding sites (data not shown).
Modulation of human IGF1 promoter activity in human
mesenchymal stem cells
The effect of the various fusion proteins on murine IGF-1
promoter activity was tested in MPCs using a luciferase reporter
assay, but a high background rendered interpretation of the results
difficult in these cells, prompting us to use human mesenchymal
stem cells (hMSC). Our recent observations have shown that
hMSC infected with an EWS-FLI1 containing retrovirus can
sustain EWS-FLI-1 expression and display a 20 fold induction of
IGF1 [17]. Studies by others have shown that downregulation of
EWS-FLI-1 expression in ESFT cell lines results in the emergence
of an hMSC phenotype [18], supporting the notion that hMSCs
may provide an ESFT origin. We therefore used hMSCs to further
explore the relationship between ESFT fusion proteins and IGF1.
A 1682 nucleotide (nt) region of the human IGF1 promoter
upstream of the exon 1 start codon (Ensemble
ENSE00001194172) was isolated and ligated to sequences
encoding the luciferase reporter gene in the pGL3 plasmid. This
promoter region has been shown to be functional or to at least
contain functional portions of the promoter in different IGF1
expressing cells, including macrophages [19] and the EWS-FLI-1
expressing Ewing’s sarcoma cell line SK-N MC [20]. A 6 fold
increase in luciferase activity in SK-N MC cells transfected with
the –1682pGL3 construct was observed compared to that in cells
bearing a promoterless construct (data not shown). IGF1 promoter
analysis using the Genomatix (http://www.genomatix.de) genome
annotation tool ‘‘Eldorado’’ showed that the region from –1682 to
+1 contains 2 separate putative promoters upstream of the exon I
start codon: GXP79580 from –782 to –64 and GXP641910 from
–1664 to –962.
MSCs were co-transfected with the –1682pGL3 construct
together with either an empty pMSCV or a pMSCV construct
containing sequences encoding the EWS-FLI-1, EWS-ERG or
FUS-ERG fusion. The EWS-WT1 fusion associated with
desmoplastic small round cell tumors (DSRCT,[21]) and a
truncated protein composed of the first 262 amino acids of FUS
with a short tag were used as controls along with FLI-1 and ERG-
1 proteins. A 12-fold increase in luciferase activity was observed in
EWS-FLI-1 expressing cells compared to empty pMSCV
transfected cells, whereas a 4.5- and a 2.5-fold increase were
observed, respectively, in cells expressing EWS-ERG and FUS-
ERG (Figure 7). The capacity of the three fusions to mediate IGF1
promoter activation in human MSCs reflected their respective
ability to induce IGF1 expression in mouse mesenchymal
progenitor cells, as assessed by real time PCR (Table 1). By
contrast, luciferase activity in cells expressing EWS-WT1, the FUS
(1-262) control protein, FLI-1 or ERG-1 was comparable to that of
cells transfected with the empty vector suggesting that neither of
Table 2. Real time PCR validation of EWS-FLI-1- and EWS-FLI-
1 R340N-induced and repressed genes 36 hours following
infection
Gene
symbol EWS-FLI-1 EWS-FLI-1 R340N
Fold increase/
decrease SD
Fold increase/
decrease SD
CITED-1 461.61 0.1 3.19 0.17
DHH 28.61 0.19 ,I 2 I
SFRP4 57.76 0.56 ,I 2 I
IGF-1 8.76 0.2 ,I 2 I
IGFBP5 47.8 0.14 ,I 2 I
IGFBP3 2.34 0.3 10.16 0.13
PODXL 10.72 0.13 4.41 0.18
KRT1-19 103.15 0.41 18.9 0.36
CDH5 24.9 0.46 2.48 1.14
ENO3 8.3 0.45 ,I 2 I
DCN 27.6 0.18 23.3 0.23
MT2 ,I 2 I 22.7 0.12
DKK3 ,I 2 I ,I 2 I
DKK2 23.3 0.198 ,I 2 I
The indicated fold increase or decrease (2) and the corresponding standard
deviation are representative of three independent experiments. Lower than
two-fold increases or decreases in absolute value are indicated.as ,I 2 I
doi:10.1371/journal.pone.0002634.t002
Table 3. Real time PCR validation of FUS-ERG fusion protein-
induced and repressed genes 36 hours following infection
Gene
symbol FUS-ERG AML FUS-ERG ESFT
Fold increase/
decrease SD
Fold increase/
decrease SD
CITED-1 229.28 0.03 80.2 0.08
DHH 28.62 0.16 22.84 0.49
SFRP4 108.67 0.09 42.83 0.21
IGF-1 5.97 0.06 2.26 0.08
IGFBP5 103.49 0.13 11.7 0.11
IGFBP3 34.1 0.53 2.83 0.27
PODXL 20.3 0.11 3.98 0.09
KRT1-19 71.13 0.146 18 0.07
CDH5 544.82 0.54 106.41 0.45
ENO3 5.19 0.08 2.49 0.06
MMP3 16.93 0.13 6.95 0.09
MT2 6.3 0.11 2.39 0.26
DKK3 22.5 0.05 ,I 2 I
DKK2 22 0.11 ,I 2 I
The indicated fold increase or decrease (2) and the corresponding standard
deviation are representative of three independent experiments. Lower than
two-fold increases or decreases in absolute value are indicated as ,I 2 I
doi:10.1371/journal.pone.0002634.t003
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the two ets family members nor the EWS and FUS portions alone
were able to activate the IGF1 promoter. Consistent with our
initial observations, the DBDM did not induce any increase in
luciferase activity (Figure 7). The integrity of the DNA binding
domain of FLI-1 in the context of the fusion is therefore necessary
for EWS-FLI-1 mediated activation of the IGF1 promoter in
MPCs and hMSC (Table 2).
GEMS analysis [22], used to search for transcription factor
binding sites (MatInspector) and sequence models (ModelInspec-
tor), of the –1682 to +1 region of the human IGF-1 promoter,
revealed the presence of potential binding sites for several different
transcription factors, including ets family members, supporting the
possibility of direct interaction of Ewing’s sarcoma fusion proteins
with the IGF-1 promoter. Comparative Genomix analysis, on the
other hand, showed no conserved putative ets binding sites in this
region, whereas other transcription factor binding sites, such as
RFX1, were found to be conserved. To define the relevance of the
2 putative promoter regions GXP79580 and GXP641910,
identified by Genomatix analysis, 3 additional luciferase fusion
plasmids were generated by restriction enzyme cleavage and
ligation to the pGL3 vector (Figure 8 A). Constructs –1098pGL3
and –913pGL3, generated respectively by XhoI/HindIII, and
KpnI/HindIII digestion, included the entire GXP79580 promot-
er, a short sequence of GXP641910 being included in the –
1098pGL3 construct. The –673pGL3 plasmid, obtained by AvaI/
HindIII digestion, contained only part of the GXP79580
promoter.
Luciferase activity, measured in human mesenchymal stem cells
transfected with an EWS-FLI-1 containing plasmid together with
the –1098pGL3 or the –913pGL3 construct, was similar, a 20%
reduction of activity being observed in both cases compared to
cells into which the entire promoter region –1682 had been
introduced. A more robust reduction of activity (70%) was
observed when the –673pGL3 construct was introduced.
Taken together these data suggest that both GXP79580 and
GXP641910 regions contribute to EWS-FLI-1 mediated IGF1
promoter activity, although a more substantial contribution is
made by the GXP79580 region. The observed difference in
contribution could be explained by the loss of potential binding
sites for different transcription factors within this region. Although
ets binding sites are plausible candidates for EWS/FLI-1 mediated
IGF-1 promoter activation, other sequences relevant to IGF-1
promoter activity could be present in the deleted segments. Among
many other binding sites lost in the –673 construct were an E-box,
Figure 6. In vivo interaction of EWS-FLI-1 with the region from –2754 to –2683 of the murine IGF1 promoter. A) Quantitative RT-PCR
analysis was performed on chromatin immunoprecipitates obtained from mouse MPCs expressing EWS-FLI-1, EWS-FLI-1 R340N mutant or an empty
pMSCV vector. Primers specific for murine GAPDH DNA were used as input DNA control. Error bars reflect results of triplicate experiments. (B) IGF1
mRNA induction by EWS-FLI-1 and EWS-FLI-1 R340N in the MPCs used for the ChIP experiments. Quantitative RT-PCR was performed using a murine
IGF1 TaqMAN probe (applied biosystems).
doi:10.1371/journal.pone.0002634.g006
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a STAT binding site which forms a sequence model (Genomatix
modelInspector) together with an ets binding site, and a Myc
associated zinc finger binding site (MAZF). Mutagenesis experi-
ments to define the role of different potential ets and other
transcription factor binding sites in the regulation of IGF-1
expression are ongoing.
Discussion
The distinguishing feature of Ewing’s sarcoma is the expression of
an aberrant transcription factor encoded by a fusion gene resulting
from a non-random chromosomal translocation. In all cases the
fusion protein is composed of the amino terminal portion of a TET
family member that provides a potent transactivating domain and
the DNA binding domain of one of several possible ets family
members. In more than 99% of cases, the TET family member is
EWS and in 85–90% of cases the ets family member is FLI-1. EWS
is fused to ERG in 5–10% of cases whereas FUS-ERG is found in
less than 1% of cases [1,2,4,12]. The difference in frequency of
association of the fusion proteins with ESFT is currently
unexplained, and could conceivably reflect the relative frequency
of the corresponding chromosomal breaks. However, our present
observations using mouse MPCs suggest that primary mesenchymal
stem cells display a markedly different degree of permissiveness for
Figure 7. IGF1 promoter activity in human mesenchymal stem cells expressing the three ESFT-associated chimeric proteins EWS-
FLI-1, EWS-ERG and FUS-ERG. Promoter activity in the presence of the EWS-FLI-1 R340N mutant, the FLI-1 and ERG-1 wild type proteins, the EWS-
WT1 fusion and the FUS(1-262)-tag protein are also shown. Luciferase activity is reported as a value relative to that measured in vector transfected
cells; error bars represent the S.E.M. of three independent experiments. The significance (p,0.01) of luciferase induction is indicated by an asterisk.
doi:10.1371/journal.pone.0002634.g007
Figure 8. Schematic representation of IGF1 promoter fragments cloned into the pGL3 basic vector (A) and the corresponding
luciferase activity (B) in human mesenchymal stem cells expressing EWS-FLI-1. Restriction sites used for cloning are indicated. The exon 1
start codon, putative promoter regions GXP79580 and GXP641910 according to GEM analysis (Genomatix) are shown. Levels of luciferase activity,
calculated as in Figure 6, are normalized to values obtained with the –1682 construct which was arbitrarily set to 100%. Error bars represent the S.E.M.
of three independent experiments.
doi:10.1371/journal.pone.0002634.g008
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the three fusion proteins. Whereas expression of EWS-FLI-1 was
tolerated in all of the cell batches tested, expression of EWS-ERG
was restricted to a fraction of the batches while stable expression of
FUS-ERG could not be achieved. The observed differential
permissiveness correlates with the relative frequency at which each
fusion accompanies ESFT cases, suggesting distinct windows of
opportunity for the different fusion proteins to display their putative
transforming properties in MPCs.
Mechanisms whereby MPCs restrict expression of EWS-ERG
and FUS-ERG remain to be elucidated. Whereas in some cases
the specific RNA was not detectable or appeared degraded, in
others protein expression could not be detected despite mainte-
nance of transcripts of appropriate length. It is conceivable that
discrete stages of MPC differentiation may account for the
observed differences in permissiveness. Alternatively, MPCs may
be composed of functionally heterogeneous cell subsets that cannot
be distinguished on the basis of the restricted number of
phenotypic markers used to characterize them. A plausible
scenario may be that a majority of these putative subsets display
a milieu that is favourable for EWS-FLI-1 expression and function,
whereas only rare subsets may tolerate expression of FUS-ERG.
Thus, the composition or differentiation stage of MPC populations
may determine whether or not expression of ESFT-associated
fusion proteins other than EWS-FLI-1 may be sustained.
The observed difference in permissiveness for fusion protein
expression could not be attributed to functional differences among
MPC batches because the same batches were used for expression
of all of the contructs.
Although EWS-FLI-1 has been shown to have the capacity to
transform primary MPCs that express functional p53 and p19ARF
[8], EWS-FLI-1 expression and transforming potential in primary
unsorted bone marrow cells were found to be facilitated by
inactivating TP53 mutations [23]. Alterations in signaling
pathways relevant to oncogenesis may therefore provide at least
one mechanism that renders primary cells permissive for ESFT-
associated fusion protein expression and susceptible to the
corresponding transforming properties.
Interestingly, FLI-1 and ERG-1 displayed higher potential
target gene similarity in the context of EWS-associated fusion
proteins than alone. It is possible that several common FLI-1 and
ERG-1 candidate targets are undetected because of the weakness
of the intrinsic transactivation domain of the two transcription
factors. The potency of EWS transactivation may provide a
mechanism to unmask such putative targets. The ability of EWS to
interact with numerous proteins implicated in transcriptional
regulation and RNA processing [24,25,26,27,28,29] may supply
an alternative explanation. Thus, it is possible that a combination
of EWS and its binding partners confer upon FLI-1 and ERG-1
the ability to induce expression of common genes. Of the fraction
of induced and repressed transcripts that were common to the
three fusion proteins, most are not known to be directly implicated
in transformation, and it is possible that the three fusion proteins
use distinct mechanisms to transform primary cells, resulting
nevertheless in tumors with an indistinguishable phenotype as
assessed by conventional histology and immunohistochemistry.
One potentially important functional similarity among the fusion
proteins in the context of ESFT pathogenesis, however, is their
ability to induce IGF1.
Recently, EWS-FLI1 was shown to transform MPCs and
produce tumors with an ESFT-like phenotype in immunodeficient
mice [8]. Three potentially relevant genes that were found to be
strongly induced were IGF1, IGFBP3 and IGFBP5. IGF-1 is
believed to play a critical role in ESFT growth and development
[8,30,31,32]. Transformation of NIH3T3 fibroblasts by EWS-FLI-
1 requires expression of IGF-1R [33] and blockade of the receptor
using antibodies [31] or small molecule receptor tyrosine kinase
(RTK) inhibitors [8,32] strongly inhibits ESFT cell growth. The
present results indicate that IGF1, IGFBP3 and IGFBP5 are
induced by all of the fusion proteins tested but not by FLI-1 and
ERG-1 alone. Importantly, induction of IGF1 and IGFBP5
requires integrity of the DBD of FLI-1 within the fusion protein
as demonstrated by the inability of the DBDM to induce either
molecule. Quantitative RT-PCR results from chromatin immu-
noprecipitates argue that EWS-FLI-1 interaction with the IGF1
promoter occurs in vivo. The observations that EWS-FLI-1
activates the IGF1 promoter as assessed by luciferase reporter
assays in human MSCs provide further support to the notion that
IGF1 is a target of EWS-FLI-1.
By contrast, the DBDM could induce IGFBP3 suggesting that in
MPCs EWS-FLI-1 does not require integrity of the DBD for
IGFBP3 upregulation. The observation that IGFBP3 was induced
in a non-DBD-dependent manner by EWS-FLI-1 in MPCs in
apparent contrast to the recent report that IGFBP3 is a direct
target of EWS-FLI-1 which is down regulated as a result of EWS-
FLI-1 expression in an ESFT cell line [34]. These contrasting
results may be explained, in part, by cell state differences. ESFT
cell lines reflect late stage tumor progression where the effect of
EWS-FLI-1 may be modulated by a variety tumor stage-associated
factors. The effect of EWS-FLI-1 and the other fusion proteins on
MPCs, on the other hand, was evaluated in primary cells at an
early time point following expression, prior to transformation and
tumor development.
Growth hormone induces IGF-1 and the robust growth
hormone spurt during puberty may help create favorable
conditions for the initial development of ESFT from mesenchymal
stem cells harboring the appropriate chromosomal translocations
and expressing the corresponding fusion proteins. Subsequent
maintenance of tumor growth may require tumor cell-autonomous
IGF-1 production and IGF1 induction may provide one
mechanism whereby EWS-FLI-1 and its ESFT-associated relatives
ensure tumor growth and progression.
Materials and Methods
Mesenchymal stem cells and cell lines
Mouse mesenchymal progenitor cells (MPCs) were isolated from
bone marrow of adult C57BL/6, wild type mice according to the
methods described in [35], and cultured on fibronectin-coated
plates (Sigma) in medium containing 2% dialyzed FCS (Sigma),
10 ng/ml EGF (Sigma), 10ng/ml PDGF-BB (R&D Systems) and
10ng/ml recombinant human leukemia inhibitory factor (Chemi-
con). Mesenchymal stem cells markers expression and differenti-
ation assays were performed as previously described [8].
Human mesenchymal stem cells were obtained as previously
described [36,37] from femoral head bone marrow of patients
undergoing total hip replacement according to the guidelines of
the ethical committee protocol 01-172 and after informed consent
of the patients. MSCs were cultured at low confluence in IMDM,
10% FCS, 10 ng/ml PDGF-BB (PeProtechEC, London,UK) and
were tested for multilineage differentiation into adipocytes,
chondrocytes and osteoblasts [36,37]. The SK-N-MC cell line
was from ATCC (Rockville, MD).
Cell cycle analysis
DNA content and cell cycle analysis were performed by flow
cytometry. Cells were centrifuged, and the pellets were gently
resuspended in 1.5mL hypotonic propidium iodide solution (PI,
50 mg/mL in 0.1% sodium citrate plus 0.1% Triton X-100;
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Sigma). The tubes were kept at 4uC in the dark overnight. The PI-
fluorescence of individual nuclei was measured by flow cytometry
using standard FACScan equipment (Becton Dickinson, Mountain
View, CA).
Constructs and cDNA Cloning
A cDNA clone encoding the type 2 EWS-FLI-1 fusion protein
was amplified from the SK-N-MC Ewing sarcoma cell line by RT-
PCR. The amplified fragment carrying an in frame v5 tag at the
39extremity was digested with XhoI and Hpa I and inserted into
the pMSCV Puro retroviral expression vector (BD Biosciences
Clontech, Palo Alto, CA).
The EWS-FLI-1 R340N DBDM was amplified by PCR using
the wt sequence as template, with the following primers:
hEWS forward XhoI:
59CCGCTCGAGCCACCATGGCGTCCACGGATTACAG
39;
hFLI-1 reverse R340N:
59 ATCATAGTAATAATTGAGGGCCCGGCTCAGCTT-
GTC 39;
hFLI-1 forward R340N:
59 CGACAAGCTGAGCCGGGCCCTCAATTATTACTAT-
GA 39;
V5 reverse Hpa I (including a stop codon):
59 GTTAACTCACGTAGAATCGAGACCGAGGAGAGG-
GTTAGGGATAGGCTTACC 39.
The amplified fragment was XhoI-HpaI-digested and inserted
into the pMSCVPuro retroviral vector.
EWS-ERG and ERG-1 fragments were amplified from
surgically resected Ewing’s sarcoma tissue by RT-PCR.
Amplified fragments, carrying a BglII restriction site at the
59end were inserted, using the pcDNA3.1/V5-HisTOPO TA
cloning kit (Invitrogen, Carlsbad, CA), into the corresponding
expression vector in frame with the V5 epitope tag. The EWS-
ERG-v5 and the ERG-1-v5 fragments were digested with BglII
and PmeI and inserted into the BglII/HpaI-digested pMSCV
Puro vector. Human FLI-1 cDNA was amplified from hMSC
RNA and inserted into EcoRI/XhoI-digested pMSCV Puro.
cDNA clones encoding the human FUS-ERG AML and FUS-
ERG ESFT fusions were obtained by PCR and inserted into
BglII/HpaI-digested pMSCV Puro. Fragments encoding exons 1-
7 or exons 1-6 of human TLS/FUS, amplified from the EST clone
IMAGE:3345294, and a fragment encoding the C-terminal
portion, starting at exon 9, of human ERG, amplified from the
EWS-ERG-v5 clone, were used in the PCR reactions.
The primer sequences were:
External ERG-v5-reverse 59GTTAGGGATAGGCTTACC-
TTCGAACCGCGGGCCGTAGTAAGTGCCCAG 39
External BglII FUS forward
59GGAAGATCTTCCCCACCATGGCCTCAAACGATTA-
TACC 39
Internal for FUS-ERG AML:
Forward59GCTTCAATAAATTTGGTGGCAGTGGCCAG-
ATCCAGCTTTGGCAGTTCC39
Reverse 59AGCTGGATCTGGCCACTGCCACCAAATT-
TATTGAAGCCACCAC39
Internal for FUS-ERG ESFT:
Forward 59GCCGTGGAGGCAGAGGCAGTGGCCAGAT-
CCAGCTTTG 39
Reverse 59CAAAGCTGGATCTGGCCACTGCCTCTGC-
CTCCACGGCCACCT 39
A cDNA control encoding the first 262 amino acids of the
human TLS/FUS protein followed by a tail of 54 random amino
acids was obtained by PCR and inserted into pMSCV Puro. The
54 random amino acid tail displayed no homology in a BLAST
search and contained none of the motifs present in the ERG-1 or
FLI-1 proteins as assessed by the SMART- Simple Modular
Architecture Research Tool [http://smart.embl-heidelberg.de].
All constructs were sequence-verified.
Retrovirus generation and infection
Expression of EWS-FLI-1, EWS-ERG, FUS-ERG (AML),
FUS-ERG (ESFT) , ERG-1 and FLI-1 in MPCs was achieved
using the Retroviral Gene Transfer and Expression (BD
Biosciences Clontech), according to the manufacturer’s recom-
mendations. Infected cells were selected in 1.5 mg/ml puromycin
for a maximum of 14 days.
RNA and genomic DNA extraction and Reverse
Transcription PCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen,
Hilden, Germany) and genomic DNA was isolated using a DNeasy
Tissue Kit (Qiagen) according to the manufacturer’s recommen-
dations. RT-PCR was performed using Super Script one step RT-
PCR with the platinum Taq kit (Invitrogen, Carlsbad, CA).
Western blot analysis
Cell lysis, SDS-PAGE and blotting were done according to
standard procedures and immunodetection was performed using
chemoluminescent substrate kits from Amersham according to the
manufacturer’s recommendations. Primary antibodies used were:
monoclonal mouse anti-V5epitope antibody (Invitrogen), mouse
anti human FLI-1 monoclonal antibody (G146-222 BD- Pharmin-
gen, San Diego, CA), monoclonal mouse anti-actin (Sigma) and
mouse IgG (Sigma). The goat anti-mouse HRP conjugated
secondary antibody was from Amersham. Densitometric analysis
was performed using the public domain image processing and
analysis program NIH image J (http://rsb.info.nih.gov/ij/).
cDNA array hybridization and cDNA array analysis
For each comparison 3 independently isolated MPC popula-
tions were used and 3 independent infections were performed.
Total RNA was extracted at 36 hours following infection. The
quality of RNA was verified by an Agilent RNA 600 nanoassay
and by measuring the 260/280 absorbance ratio. Quality-tested
total RNA was amplified using the RiboAmp RNA Amplification
Kit (Arcturus, Moutainview, CA) and processed using a reverse
transcription based method of label incorporation to yield labeled
cDNA as previously described [8]. Following hybridization and
washing, microarrays were imaged using a DNA microarray
scanner (agilent technologies) and array analysis and quality
control were performed as described in [8].
Statistical analysis of the expression data
RNA derived from EWS-FLI-1, EWS-ERG, FUS-ERG (AML),
FUS-ERG (ESFT), ERG-1 and FLI-1 expressing MPC popula-
tions were all subjected to microarray analysis; five m17k
microarrays (among which 2 were dye swaps) were performed
for each population, comparing cells expressing the protein of
interest with the corresponding empty vector control cells.
Differentially expressed genes were then identified with the rank
product method [38] as implemented in the ‘‘RankProd’’
Bioconductor package [39]. We retained for further analysis the
clones identified as differentially expressed with a false discovery
rate of 5%. The statistical significance of the overlap between
differentially expressed genes in different translocations was
evaluated with Fisher’s exact test.
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Real time quantitative RT-PCR
cDNA was obtained using an M-MLV reverse transcriptase and
RNAse H minus (Promega). Typically 500 ng of template total
RNA and 250 ng of random hexamers were used per reaction.
Real time-PCR amplification was performed in an ABI Prism
7700 instrument (Applied Biosystems), using Taq Man Universal
PCR mastermix and Assays-On-Demand Taq Man probes for
IGF1, IGFBP5, IGFBP3, SFRP4, DKK2, DCN, MT2 and
MMP3.
For real time quantitation of CITED1, DHH, PODXL, KRT1-
19, CDH5, ENO3 and DKK3 RNAs, the Universal Probe
Library system (Roche Rotkreuz, Switzerland) was used and
primers were designed according to the ProbeFinder software
(http://www.roche-applied-science.com).
The following primers were designed:
ENO3:
forward59CCGGGAAATCCTGGACTC39
reverse 59CAGCTGCTCGGAATCGAC39
CDH5:
forward59TCACCTTCTGTGAGGAGATGG39
reverse 59GATGATCAGCAAGGTAATCACTGT39
PODXL:
forward59GGATCTCCCAGAGGAAGGAC39
reverse 59CAAGGTTGGGTTGTCATGGT39
DKK3:
forward59CTCAATGAGATGTTTCGAGAGGT39
reverse 59 CTTCTTCCGCCTCCATCTC 39
CITED1:
forward59CTAGGTCGCTTCGTCCGTA39
reverse 59AGCTGGGCCTGTTGGTCT39
KRT1-19:
forward59TGGAGATGCAGATTGAGAGC39
reverse 59TCCTCAGGGCAGTAATTTCC39
For GAPDH amplification, rodent GAPDH control reagent
(Applied Biosystems) was used. Relative quantitation of target,
normalized with an endogenous control (GAPDH), was performed
using a comparative Ct method (Applied Biosystems).
IGF1 promoter analysis and cloning
In silico IGF1 promoter analysis was performed using the
Genomatix (http://www.genomatix.de) genome annotation tool
‘‘Eldorado’’. Specifically, GEMS analysis was used with both
MatInspector and ModelInspector tools to search for putative
transcription factor binding sites and sequence models [22].
Comparative genomix was also used.
The human IGF1 promoter sequence from position –1682 to
+1 (start codon on exon 1) was amplified from hMSC genomic
DNA using primers: 59CCCAAGCTTGGGTGCTTCTGAAG-
TACAAAGTCTG39 and 59GAAGATCTTCAAATGTTGCT-
GAACATAGTGCACCATTG39.
The amplified fragment was ligated into the BglII and HindIII
cloning sites of the pGL3-basic vector (promega) and sequence-
verified. Smaller IGF1 promoter fragments (21098, 2913 and –
673) were obtained from the –1682pGL3 construct by digestion
and re-ligated into the pGL3-basic vector. Restriction enzyme
digestion was as follows: HindIII/XhoI to obtain the 21098
fragment, : HindIII/KpnI to obtain the –913 fragment and
HindIII/AvaI to obtain the –673 fragment.
Transient transfection and luciferase assays
2 mg of empty pMSCV plasmid or pMSCV encoding human
FLI-1, ERG-1, EWS-FLI-1, EWS-ERG, FUS-ERG, EWS-WT1
and the EWS-FLI-1 R340N DBD mutant were introduced by
nucleofection along with 2 mg of a pGL3 basic vector or the
pGL3-IGF1 promoter construct (21682pGL3) into freshly isolated
human mesenchymal stem cells using a nucleofector II device and
the appropriate solution according to manufacturer’s recommen-
dation (Amaxa GmbH, Koeln, Germany). For promoter region
analysis, 2 mg of pMSCV encoding human EWS-FLI-1 were
introduced by nucleofection along with 2 mg of a pGL3 basic
vector or one of the pGL3-IGF1 promoter constructs. General
transfection efficiency was controlled using a pMAX-GFP control
vector (AMAXA) or a pGL3 promoter vector containing a SV40
promoter. A 75% efficiency was calculated in MSCs using
nucleofection. Transfection efficiency for both fusion proteins
and luciferase reporter plasmid was more specifically controlled by
PCR or RT-PCR performed on RNA or DNA using primers
specific for either luciferase or each of the fusion genes. Luciferase
activity was measured 48 hours later on cleared cell lysates using
the luciferase assay system (Promega) according to manufacturer’s
recommendations. 3 independent experiments were performed
using 2 different batches of hMSCs. Reporter luciferase activity
was measured in triplicate, mean values were corrected for total
cell number and reported as relative values to vector transfected
cells. Total protein normalization was not possible due to the
presence in the luciferase kit lysis buffer of components that disrupt
common total protein measurement assays. Nevertheless parallel
experiments were performed with fractions of the same cell
populations lysed in appropriate buffer to control the correspon-
dence between cell number and total proteins.
Statistical significance was determined with a 2 sided t-test on
the logarithm of the relative activity.
Chromatin immunoprecipitation
ChIP was performed according to the Abcam protocol (Abcam,
Cambridge, UK). Briefly 16107 mouse MPCs expressing either
EWS-FLI-1, EWS-FLI-1 R340N mutant or an empty pMSCV
vector, were cross-linked with 1% folmaldehyde for 10 min. After
addition of 0.125 M glycine and washing in cold PBS, cells were
lysed and the chromatin fraction was sheared to roughly 700bp
fragments by sonication. About 1/15 of the lysate was digested
with proteinase K, phenol chloroform extracted, ethanol-precip-
itated and stored as input DNA. Immunoprecipitation was
performed using a chip-grade rabbit polyclonal anti V5 antibody
(Abcam) and herring sperm DNA blocked protein A-sepharose
beads. The cross linkage was reversed using proteinase K and the
DNA purified by phenol/chloroform extraction and ethanol
precipitation. Quantitative PCR on the immunoprecipitate and
on input DNA was performed on a ABI Prism 7700 instrument
(Applied Biosystems). Primers complementary to the mouse IGF1
promoter region from –2754 to –2683 and control primers
spanning a region 14000 bp upstream of the IGF1 exon 1 start
codon were designed using the Assay Design Center ProbeFinder
(Roche) and were as follows:
Forward: 59 TGCCTGGCAACTAGGACAA 39
Reverse: 59 GATCGAAAGGCAGCTCTCAG 39
Control Forward: 59 AGGTCCAAAAGTTGCATCAGA 39
Control Reverse: 59 CGAGACTCCCTGCCTTAAAA 39
Primers complementary to murine GAPDH DNA were used as
the Input control.
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